Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 35,163 | -13,345 | 124,453 | 79,669 | -37,604 |
| Depreciation Amortization | 15,356 | 7,517 | 30,090 | 23,326 | 15,948 |
| Income taxes - deferred | -549 | -13,532 | 22,684 | 12,113 | -9,169 |
| Accounts receivable | -7,441 | 6,409 | -21,737 | -19,650 | -3,341 |
| Other Working Capital | -1,116 | 5,885 | -12,665 | -21,954 | -11,339 |
| Other Operating Activity | 31,296 | 55,757 | -93,466 | -70,060 | 35,859 |
| Operating Cash Flow | $72,709 | $48,691 | $49,359 | $3,444 | $-9,646 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 219,119 | -101,529 | -363,221 | -349,877 | -8,703 |
| PPE Investments | -2,894 | -228 | -11,314 | -1,256 | -2,249 |
| Net Acquisitions | N/A | N/A | -813 | N/A | N/A |
| Purchase Sale Intangibles | 9,500 | 6,979 | 10,261 | N/A | 5,179 |
| Other Investing Activity | 10,545 | 7,410 | -1,974 | -8,085 | 5,179 |
| Investing Cash Flow | $226,770 | $-94,347 | $-377,322 | $-359,218 | $-5,773 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 700,000 | N/A | 460,000 | 460,000 | 0 |
| Debt Repayment | -195,790 | N/A | -113,250 | -113,250 | N/A |
| Common Stock Issued | 130,355 | 7,654 | 114,891 | 105,593 | 12,461 |
| Common Stock Repurchased | -60,000 | N/A | -15,000 | -15,000 | 0 |
| Other Financing Activity | -42,264 | -21,787 | -18,418 | -17,450 | -2,213 |
| Financing Cash Flow | $532,301 | $-14,133 | $428,223 | $419,893 | $10,248 |
| Exchange Rate Effect | -5 | -44 | 2,360 | 2,950 | 3,350 |
| Beginning Cash Position | 174,927 | 174,927 | 72,307 | 72,307 | 72,307 |
| End Cash Position | 1,006,702 | 115,094 | 174,927 | 139,376 | 67,669 |
| Net Cash Flow | $831,775 | $-59,833 | $102,620 | $67,069 | $-4,638 |
| Free Cash Flow | |||||
| Operating Cash Flow | 72,709 | 48,691 | 49,359 | 3,444 | -9,646 |
| Capital Expenditure | -2,894 | -228 | -11,314 | -1,256 | -2,249 |
| Free Cash Flow | 69,815 | 48,463 | 38,045 | 2,188 | -11,895 |